Randomised comparison of losartan vs. captopril on quality of life in elderly patients with symptomatic heart failure: The losartan heart failure ELITE quality of life substudy

Quality of Life Research

Volumn 9, Issue 4, 2000, Pages 377-383

  Cowley, A J ^a   Wiens, B L ^b   Segal, R ^b   Rich, M W ^c   Santanello, N C ^b   Dasbach, E J ^b   Pitt, B ^d  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

^b MERCK RESEARCH LABORATORIES   (United States)

^c BARNES JEWISH HOSPITAL   (United States)

^d UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

Author keywords

Captopril; Heart failure; Losartan; Missing data; Quality of life

Indexed keywords

CAPTOPRIL; LOSARTAN;

AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM;

EID: 0033671831     PISSN: 09629343     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008948930206     Document Type: Article

References (29)

1. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure
2. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the survival and ventricular enlargement trial
3. Effect of direct vasodilation with hydralazine versus angiotensin-converting enzyme inhibition with captopril on mortality in advanced heart failure: The Hy-C trial
4. Angiotensin II receptor antagonists in heart failure: Rationale and design of the evaluation of losartan in the elderly (ELITE) trial
5. Bradykinin-mediated effects of ACE inhibitors
6. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy: A review of the literature and pathophysiology
7. Post-marketing surveillance of captopril (for hypertension): A preliminary report
8. Effects of modulators of the renin-angiotensin-aldosterone system on cough
9. Low rates of angiotensin-converting enzyme inhibitor use in congestive heart failure
10. Angiotensin II receptors and angiotensin II receptor antagonists
11. On behalf of the ELITE study investigators. Randomised trial of losartan versus captopril in patients over 65 with heart failure (evaluation of losartan in the elderly, ELITE)
12. Randomized trial of losartan versus captopril on mortality in patients with symptomatic heart failure: The losartan heart failure survival study-ELITE II
13. The sickness impact profile: Development and final revision of a health status measure
14. Assessment of patient outcome with the Minnesota living with heart failure questionnaire: Reliability and validity during a randomised double-blind placebo-controlled trial of pimobendan
15. Validity of the Minnesota living with heart failure questionnaire as a measure of therapeutic response to enalapril or placebo
16. Including deaths when measuring health status over time
17. Testing for treatment differences with dropouts present in clinical trials - A composite approach
18. Multiple test procedure for arbitrary dependence structures
19. An improved Bonferroni procedure for multiple tests of significance
20. A stagewise rejective multiple test procedure based on a modified Bonferoni test
21. Evaluating health-related quality of life outcomes in patients with congestive heart failure. A review of recent randomised controlled trials
22. Effects of ACE inhibitor therapy on quality of life in patients with heart failure
23. Quality of life with ACE inhibitors in chronic heart failure
24. Effect of ACE inhibitors on the quality of life of patients with heart failure
25. Effects of enoximone on quality of life
26. Treatment of severe heart failure: Quantity or quality of life? A trial of enoximone
27. Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the flosequinan-ACE inhibitor trial (FACET)
28. Measurement of health status: Ascertaining the minimal clinically important difference
29. The randomized clinical trial